Revive Therapeutics Stock News

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) announced the publication of a scientific article evaluating the impact of medication, including Bucillamine, on antibody response to SARS-CoV-2 mRNA vac

  Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19   TORONTO, Canada -- April 12, 2022 -- InvestorsHub NewsWire -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company's U.S. Food & Drug...

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) has updated on its Phase 3 clinical trial for Bucillamine in coronavirus (COVID-19), saying it is still targeting the second quarter this year to meet it

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19   Expected to seek DSMB approval to proceed with EUA application to the FDA in Q2-2022   Ongoing regulatory package activities for submission to international regulatory authorities for drug approvals   Toronto, Ontario, Canada -- March 29, 2022 -- InvestorsHub NewsWire -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RV...

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) has provided an update on the company's US Food and Drug Administration (FDA) Phase 3 clinical trial (NCT04504734) to evaluate the safety and efficacy of

                              HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical Research The naturally derived GMP psilocybin will be exported through distribution partner Mycrodose Therapeutics Inc. to the University of Wisconsin-Madison, Contract Research Organization for Revive Therapeutics   Vancouver, BC, February 24, 2022 -- Inves...

The naturally derived GMP psilocybin will be exported through distribution partner Mycrodose Therapeutics Inc. to the University of Wisconsin-Madison, Contract Research Organization for Revive Therapeutics The naturally derived GMP psilocybin will be exported through distribution partner Mycrodose Therapeutics Inc. to the University of Wisconsin-Madison, Contract Research Organization for Revive Therapeutics

 Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation  TORONTO, February 15, 2022 -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the U.S. Food and Drug Administration ("FDA") has granted Orphan...

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for Bucillamine for the prevention of ischemia-reperfu

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19Ethics Committee approval to proceed with Phase 3 clinical trial in Turkey13 clinical sites selected to date in TurkeyTORONTO, Feb. 14, 2022 -- InvestorsHub NewsWire -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to prov...

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) announced it has now selected an initial 13 sites in Turkey for its US FDA Phase 3 clinical trial for Bucillamine in coronavirus (COVID-19). The company,

GAINERS: Revive Therapeutics (OTC: RVVTF ) shares closed up 2.51% at … Full story available on Benzinga.com

Revive Therapeutics (OTC:RVVTF) shares closed up 14.94% at $0.25 ATAI Life Sciences (NASDAQ:ATAI) shares closed up 3.53% at $5.58

Revive Therapeutics said 701 patients have been dosed in a phase 3 trial of Bucillamine in patients with mild to moderate COVID-19

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 701 subjects dosed to date Initiating enrollment activities in Turkey as part of its clinical diversification plans to support global regulatory approvals On-track to complete enrollment in Q1-2022 and FDA submission thereafter Commencing regulatory package activities for submission to international regulatory authorities for drug approvals TORONTO, Canada -- January 19, 2022 -- Inves...